Barclays
LKFT

Barclays’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Barclays’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,800
Closed -$380K – 5036
2024
Q1 		$380K Sell
11,800
-100
-0.8% -$3.72K ﹤0.01% 3761
2023
Q4 		$484K Sell
11,900
-11,900
-50% -$438K ﹤0.01% 3896
2023
Q3 		$822K Buy
+23,800
New +$927K ﹤0.01% 2480

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Barclays's LKFT Position: Q1 2026 in Review

Barclays reduced its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 92% in Q1 2026, selling an estimated $72.1K and leaving 178 shares worth $5.34K. The position accounts for ﹤0.01% of the portfolio, ranked #4766.

Barclays first reported a position in LKFT in Q2 2015 and has held it in 25 quarters since. The position peaked at $12.1M in Q4 2019. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

  • Barclays held 178 shares of Lakefront Biotherapeutics American Depositary Shares worth $5.34K as of Q1 2026.
  • Barclays sold 2,177 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $72.1K.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4766 holding.
  • Barclays first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2015 and has held it in 25 quarters since.
  • Barclays's Lakefront Biotherapeutics American Depositary Shares position peaked at $12.1M in Q4 2019.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.